ASH: Janssen keeps up CLL progress

11 December 2023
janssen-big-1

The Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has presented new long-term follow-up data at the 2023 American Society of Hematology (ASH) Annual Meeting from the Phase III GLOW and Phase II CAPTIVATE studies of first-line, fixed-duration treatment with Imbruvica (ibrutinib) plus AbbVie’s (NYSE: ABBV) Venclexta (venetoclax).

The GLOW study demonstrated an estimated 84.5% overall survival (OS) rate at 54 months, among older or comorbid patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with the combination, compared to 63.7% for patients treated with chlorambucil plus obinutuzumab.

"Deep and durable responses, including in higher-risk patients"Phase II results from the CAPTIVATE study, which used a similar Imbruvica and Venclexta regimen to the GLOW study, showed deep remissions with clinical meaningful progression-free survival (PFS) with this combination.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology